Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.


CSE:QNTM - Post by User

Post by DavidRosenbergon May 02, 2023 3:52pm
109 Views
Post# 35425919

New

New
New milestone for psychedelic-assisted psychotherapy
 
In July 2023, the AMA is set to release a new code, effective January 1, 2024, which will allow healthcare providers to bill for psychedelic-assisted psychotherapy services. The CPT Editorial Panel has accepted the addition of four Category III codes (X088T, X089T, X090T) and related guidelines for reporting psychedelic drug monitoring services. These temporary codes identify emerging technologies, services, and procedures not yet widely established or reimbursed by payers. Psychedelic drug therapy uses drugs like ketamine, psilocybin, and MDMA alongside therapy sessions to treat mental health conditions such as depression, anxiety, and PTSD.
 
Significance:
1 The new AMA code will enable healthcare providers to bill for psychedelic-assisted psychotherapy services.
2 Stimulates more research into potential benefits and paves the way for regulatory approval.
3 Collaboration between MAPS PBC and COMPASS Pathways aims to facilitate reimbursement and access to psychedelic therapies in the US if approved by the FDA.
 
 Potential pitfalls:
1 Psychedelic therapy is a new and emerging field, which may face skepticism and regulatory hurdles.
2 As Category III codes are temporary, long-term reimbursement and coverage by payers are uncertain.
3 Psychedelic-assisted therapies must still clear FDA approval for widespread adoption.
 
This milestone highlights the growing recognition of psychedelic drug therapy as a valuable treatment option for mental health conditions. While there are potential pitfalls, such as regulatory hurdles and skepticism, the new AMA code is a significant step forward in making these innovative therapies more accessible to those in need. 
 
Disclaimer: The opinions in this post are my own and may not represent those of my past employers or other companies. This post is for informational purposes only and should not be considered professional advice. Consult a qualified professional before making decisions based on this information. Investing in securities carries risks, including the potential loss of principal. #NotFinancialAdvice
 
<< Previous
Bullboard Posts
Next >>